GTBP logo

GTBP
GT Biopharma Inc

2,505
Mkt Cap
$15.12M
Volume
839,186.00
52W High
$3.85
52W Low
$0.261
PE Ratio
-0.03
GTBP Fundamentals
Price
$0.435
Prev Close
$0.4193
Open
$0.41
50D MA
$0.3919
Beta
0.70
Avg. Volume
618,072.36
EPS (Annual)
-$6.25
P/B
1.95
Rev/Employee
$0.00
$2.57
Loading...
Loading...
News
all
press releases
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic PR Newswire SAN FRANCISCO, May 18, 2026 Issued on behalf of GT Biopharma, Inc.SAN FRANCISCO, May 18, 2026 /PRNewswire/ -- USA News Group...
PR Newswire·3d ago
News Placeholder
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...
PR Newswire·7d ago
News Placeholder
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
GT Biopharma doses first patient in Phase 1 GTB-5550 trial targeting B7-H3-positive solid tumors with subcutaneous TriKE therapy.read more...
Benzinga·7d ago
News Placeholder
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know
GT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·2mo ago
News Placeholder
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Zacks·2mo ago
News Placeholder
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape PR Newswire VANCOUVER, BC, Jan. 16, 2026 Issued on behalf...
PR Newswire·4mo ago
News Placeholder
GT Biopharma Submits IND For GTB-5550 TriKE To Treat Solid Tumors
(RTTNews) - GT Biopharma, Inc. (GTBP) on Thursday said it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for GTB-5550 TriKE, designed to target...
Nasdaq News: Markets·4mo ago
News Placeholder
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.read more...
Benzinga·4mo ago
News Placeholder
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines PR Newswire...
PR Newswire·5mo ago
<
1
2
...
>

Latest GTBP News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.